Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation. Issue 12 (15th October 2021)

• Record Type: Journal Article
• Authors: Yoshimoto, Goichi; Mori, Yasuo; Kato, Koji; Odawara, Jun; Kuriyama, Takuro; Ueno, Toshiyuki; Obara, Teppei; Yurino, Ayano; Yoshida, Shuro; Ogawa, Ryosuke; Ohno, Yuju; Iwasaki, Hiromi; Eto, Tetsuya; Akashi, Koichi; Miyamoto, Toshihiro
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 12(2021)
• Page Start: 2939
• Page End: 2948
• Publication Date: 2021-10-15
• Subjects: Azacitidine -- AML -- relapse after allo-HSCT -- second allo-HSCT; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1941937
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: We retrospectively analyzed 38 patients with AML who received azacitidine (AZA) to treat disease relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients with objective response (OR) ( n = 20) after AZA had significantly higher 2-year overall survival (OS) (45.0% vs 5.6%; p = 0.004) than progressive disease. The 2-year OS was significantly higher in the retransplant group ( n = 23) than in the nonretransplant group ( n = 15) (34.8% vs 13.3%; p = 0.034). We analyzed 167 patients who underwent the second allo-HSCT to clarify the impact of pretransplant AZA after the second allo-HSCT. Patients in the AZA group ( n = 21) had significantly higher 2-year disease-free survival (DFS) (32.7% vs 14.5%; p = 0.012) and OS (38.1% vs 17.5%; p = 0.044) than those in the SOC group ( n = 146). Our data demonstrate that AZA is an effective and well-tolerated bridging therapy to the second allo-HSCT.